UroGen Pharma Ltd. /zigman2/quotes/202929873/composite URGN -1.27% a biopharmaceutical company dedicated to building novel solutions that treat specialty cancers and urologic diseases because patients deserve better options, today announced that it will participate in fireside chats at the following conferences in March:
Cowen and Company 40 [th] Annual Health Care Conference
Tuesday, March 3 [rd]
11:20 AM Eastern Time
Oppenheimer 30 [th] Annual Healthcare Conference
Wednesday, March 18 [th]
1:35 PM Eastern Time
New York, NY
A live audio webcast of each event will be available on the Investors section of UroGen's website, www.urogen.com . A replay of each webcast will be available on the website for approximately two weeks.
About UroGen Pharma Ltd.
UroGen is a biopharmaceutical company dedicated to building novel solutions that treat specialty cancers and urologic diseases because patients deserve better options. UroGen has developed RTGel™ reverse-thermal hydrogel, a proprietary sustained release, hydrogel-based platform technology that has the potential to improve therapeutic profiles of existing drugs. UroGen’s sustained release technology is designed to enable longer exposure of the urinary tract tissue to medications, making local therapy a potentially more effective treatment option. UroGen’s lead investigational candidates, UGN-101 (mitomycin gel) for instillation, and UGN-102 (mitomycin gel) for intravesical instillation, are designed to ablate tumors by non-surgical means and to treat several forms of non-muscle invasive urothelial cancer, including low-grade upper tract urothelial cancer and low-grade non-muscle invasive bladder cancer, respectively. UroGen is headquartered in Princeton, NJ with operations in New York, NY and Israel. Visit www.urogen.com to learn more or follow us on Twitter, @UroGenPharma .
View source version on businesswire.com: https://www.businesswire.com/news/home/20200225005069/en/
SOURCE: UroGen Pharma Ltd.
Copyright Business Wire 2020